Search bioRxiv⌕ Search

Biology subjects

Zhang, G.-X.

Publications and source records attributed to Zhang, G.-X..

7 recordsLinked to original sources

Beclin-1 restrains aldosterone signaling via autophagic degradation of the mineralocorticoid receptor to protect against cardiovascular injury

Cells deploy adaptive programs to maintain homeostasis under stress, yet mechanisms counteracting damage triggered by transmembrane signaling remain poorly defined. Using a hyperaldosteronism model, we examined how autophagy regulates aldosterone-mediated mineralocorticoid receptor (MR) activation. In human umbilical vein endothelial cells (HUVECs), aldosterone induced autophagy, as evidenced by elevated Beclin-1, an increased LC3-II/LC3-I ratio, and reduced SQSTM1/p62. Aldosterone also promoted MR translocation from the cytosol to the nucleus. Co-immunoprecipitation and immunofluorescence revealed direct interaction and colocalization between MR and Beclin-1, as well as enhanced MR-lysosome association. Domain mapping showed that the Beclin-1 middle domain (161-241 AA) binds the MR C-terminal region (601-984 AA). Bioinformatic prediction and ChIP-qPCR confirmed that MR occupies the promoters of IL-1{beta}, IL-6, and TNF- upon aldosterone stimulation. Beclin-1 overexpression attenuated MR nuclear translocation, promoter binding, and inflammatory cytokine expression, whereas Beclin-1 knockdown reversed these effects. In vivo, aldosterone-infused Beclin-1 transgenic (Becn1-tg) mice exhibited lower blood pressure, reduced aortic medial thickening, and attenuated cardiac hypertrophy relative to wild-type controls, with no difference in body weight. Our findings identify Beclin-1 as a critical negative regulator of aldosterone signaling through an autophagy-dependent negative feedback loop. By interacting with MR and directing it toward lysosomal sequestration, Beclin-1 limits MR nuclear translocation and transcriptional activity, thereby mitigating aldosterone-induced vascular inflammation and cardiovascular injury. HighlightsAldosterone activates autophagy and promotes MR-Beclin-1 interaction in HUVECs Beclin-1 binds the C-terminal MR domain and directs MR to lysosomal degradation Beclin-1 overexpression suppresses MR nuclear translocation and cytokine gene activation Beclin-1 transgenic mice are protected from aldosterone-induced cardiovascular injury

molecular biology↗

Astrocyte-derived extracellular vesicles as antigen-specific therapy for neuromyelitis optica spectrum disorder in the mouse model

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system (CNS), characterized by Th17 cell responses and serum antibodies against the water channel aquaporin-4 (AQP4) on astrocytes. To avoid systemic immunosuppression by current therapies, an approach is to induce antigen (Ag)-specific tolerance by injecting an AQP4 epitope used to trigger the disease (e.g., AQP4201-220). The prerequisite for Ag-specific therapy is identification of the target Ag; however, dozens of epitopes of AQP4 and certain non-AQP4 astrocyte Ags have been identified as auto-Ags in NMOSD patients and in animal models. This uncertainty regarding relevant astrocyte Ags would hinder the translation of this and similar experimental strategies into Ag-specific therapy for NMOSD patients. In our study, we developed a therapeutic approach for an experimental NMOSD (eNMOSD) mouse model that relies on astrocyte-derived extracellular vesicles (AST-EVs), which theoretically contain all astrocyte Ags. Intravenous injection of AST-EVs mitigates disease progression in an AQP-4 Ag-dependent manner in the eNMOSD model with ongoing disease. AST-EVs suppressed inflammation by decreasing immune cell infiltration of the CNS, inducing T cell apoptosis, and increasing the frequency of regulatory T cells and IL-35-producing B cells. Furthermore, we defined that IFN-{gamma} is crucial for successful i.v. tolerance induction by AST-EVs in eNMOSD. These novel findings represent a pioneering and considerable step toward a new therapeutic approach for NMOSD.

immunology↗

GM-CSF production by immune cells in steady state and autoimmune neuroinflammation mapped using fate reporting mice

The full GM-CSF expression spectrum in immune cells remains unclear, while CD4{square} T cells are the primary source. Using novel GM-CSF reporter/fate reporter transgenic mice, we tracked ongoing and past (YFP+) GM-CSF expression in various immune cells. GM-CSF was produced by diverse immune cells, including CD4+, CD8+, {gamma}{delta} T, NK, B, and CD11b+ cells, with expression patterns varying by cell type and organ with liver CD4+ T cells and NK cells showing the highest expression history in both naive and mice with EAE. GM-CSF expression was transient and permanently lost in most cells over time. In a mouse model of multiple sclerosis, effector memory CD4{square} T cells were the dominant CNS GM-CSF source, with higher expression than in other organs. CD4+YFP+ T cells, strongly expressing CXCR6, produced multiple cytokines. Transcriptomic analysis showed distinct gene expression profiles in effector memory CD4+ T cells compared to naive cells. YFP{square} Tregs represent functionally distinct subsets mirroring effector Th cells, expressing cytokines associated with Th lineages, especially during neuroinflammation. These findings identified distinct GM-CSF cellular sources across organs, highlighting a transient tissue microenvironment influence on GM-CSF production linked to CXCR6 expression.

immunology↗

CD11c+ CD8 T cells cause IFN-g-dependent autoimmune neuroinflammation that is restrained by PD-1 signaling.

In multiple sclerosis (MS) lesions, CD8 T cells outnumber CD4 T cells, suggesting that they contribute to MS pathology. However, little is known on the role of CD8 T cells in MS, partially due to the nearly ubiquitous use of experimental autoimmune encephalomyelitis (EAE) models that are mediated by CD4 T cells, with no CD8 T cell contribution. Importantly, MS and EAE differ in both their distribution of CNS lesions and their symptoms, indicating differences in CNS inflammation. MS lesions are more prevalent in the brain, while EAE lesions are more frequent in the spinal cord. Additionally, neurologic deficits in MS rarely parallel the paralysis typical for CD4 T cell-mediated EAE (CD4-EAE). In contrast, CD8-EAE models suggest that CD8 T cells preferentially cause brain inflammation, but little is known regarding how brain and spinal cord inflammation may differ, and how CD8 T cells may contribute to those differences. We have established an adoptive CD8-EAE mouse model characterized by brain-centered inflammation, severe ataxia, and weight loss. CNS inflammation in the brain and spinal cord differed in immune cell numbers, cellular composition, and inflammatory signatures. CD8-EAE could be suppressed by blocking IFN-{gamma}, and exacerbated by blocking PD-1, with concomitant changes in numbers of CNS-infiltrating monocytes. Most CD8 T cells in the CNS were CD11c+, suggesting that they are the pathogenic subset. We describe a robust CD8-EAE model, identify differences between brain and spinal cord inflammation, and characterize mechanisms that control CD8 T cell-mediated neuroinflammation, thereby furthering understanding of these cells in EAE/MS. Brief SummaryCD8 T cells are understudied in MS due to a lack of suitable animal models. We developed a CD8 T cell dependent model of MS.

immunology↗

Mechanism of glucocorticoid receptor activation regulated expression of thrombospondin-1

Objective: Thrombospondin-1 (TSP-1) plays an important role in platelet activation and aggregation and aggravates thrombosis. Chronic stress can cause a variety of diseases, including coagulation disorders, increased thrombosis, atherosclerosis, and a series of cardiovascular and cerebrovascular diseases. However, it is still unknown how chronic stress regulates the expression of TSP-1 after glucocorticoid receptor activation. Approach and Results: rats chronic unpredictable mild stress model was applied and the changes of TSP-1 and microRNAs in plasma were examined. Effects of glucocorticoid receptor activation on human umbilical vein endothelial cells and platelets were observed. Glucocorticoid receptor (GR) activation upregulated the expression of TSP-1 and downregulated the expression of microRNA-1-3p accompanied with increase of phosphorylation of p38 mitogen-activated protein kinase (MAPK) and argonaute-2 (AGO-2). Blockade of p38 MAPK phosphorylation resulted in decrease of phosphorylation level of AGO-2, increase of microRNA-1-3p expression, and decrease of TSP-1 expression. Transfection of AGO-2 Y393F point mutant plasmid, increased microRNA-1-3p expression and decreased TSP-1 expression, transfection of microRNA-1-3p mimic also decreased TSP-1 expression, while transfection of microRNA-1-3p inhibitor increased TSP-1 expression. Finally, GR activation led to an increase in the phosphorylation level of p38 MAPK in platelets and an increase in the level of TSP-1 in the supernatant. Conclusions: our study demonstrates that GR activation in HUVEC stimulates the phosphorylation of p38 MAPK, which in turn promotes the phosphorylation of AGO-2 and inhibits the maturation of microRNA-1-3p, leading to elevated expression of TSP-1, GR activation in platelets leads to the release of TSP-1. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=147 SRC="FIGDIR/small/536820v1_ufig1.gif" ALT="Figure 1"> View larger version (45K): org.highwire.dtl.DTLVardef@86e8ecorg.highwire.dtl.DTLVardef@126094eorg.highwire.dtl.DTLVardef@2d13c3org.highwire.dtl.DTLVardef@16c79c3_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical AbstractC_FLOATNO HSS: Hydrocortisone sodium succinate C_FIG

pathology↗

Targeting CSF-1 ameliorates experimental autoimmune encephalomyelitis by depleting inflammatory monocytes and microglia in the central nervous system without affecting quiescent microglia.

The receptor for colony stimulating factor 1 (CSF-1R) is important for the survival and function of myeloid cells that mediate pathology during experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). CSF-1 and IL-34, the ligands of CSF-1R, have similar bioactivities but distinct tissue and context-dependent expression patterns, suggesting that they have different roles. This could be the case in EAE, given that CSF-1 expression is upregulated in the CNS, while IL-34 remains constitutively expressed. We found that targeting CSF-1 with neutralizing mAb halted ongoing EAE, with efficacy superior to CSF-1R inhibitor BLZ945, whereas IL-34 neutralization had no effect, suggesting that pathogenic myeloid cells were maintained by CSF-1, not IL-34. Both anti-CSF-1- and BLZ945-treatment greatly reduced numbers of monocyte-derived cells and microglia in the CNS. However, anti-CSF-1 selectively depleted inflammatory microglia and monocytes in inflamed CNS areas, whereas BLZ945 depleted virtually all myeloid cells, including quiescent microglia, throughout the CNS. Anti-CSF-1 treatments reduced the size of demyelinated lesions, and microglial activation in the grey matter. Lastly, we found that bone marrow-derived immune cells were the major mediators of CSF-1R-dependent pathology, while microglia played a lesser role. Our findings suggest that targeting CSF-1 could be effective in ameliorating MS pathology, while preserving the homeostatic functions of myeloid cells, thereby minimizing risks associated with total ablation of CSF-1R-dependent cells. Significance StatementMultiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are autoimmune diseases characterized by accumulation of myeloid immune cells into the central nervous system (CNS). Both harmful and beneficial myeloid cells are present in EAE/MS, and a goal of MS therapy is to preferentially remove harmful myeloid cells. The receptor for CSF-1 (CSF-1R) is found on myeloid cells and it is important for their survival. CSF-1R can bind two ligands, CSF-1 and IL-34, but is unknown whether their functions in EAE/MS differ. We found that blocking CSF-1 depleted only harmful myeloid cells in the CNS and suppressed EAE, whereas blocking IL-34 had no effect. Thus, we propose that blocking CSF-1 could be a novel therapy for MS.

immunology↗

A fast genetically encoded fluorescent sensor for faithful in vivo acetylcholine detection in mice, fish, worms and flies

Here we design and optimize a genetically encoded fluorescent indicator, iAChSnFR, for the ubiquitous neurotransmitter acetylcholine, based on a bacterial periplasmic binding protein. iAChSnFR shows large fluorescence changes, rapid rise and decay kinetics, and insensitivity to most cholinergic drugs. iAChSnFR revealed large transients in a variety of slice and in vivo preparations in mouse, fish, fly and worm. iAChSnFR will be useful for the study of acetylcholine in all animals.

neuroscience↗